Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC

Key Points

• Vanguard Group boosted its Celcuity stake 23.5% in Q3 to 2,059,047 shares — about 4.85% of the company, valued at roughly $101.7 million.
• Analyst sentiment is broadly positive with an average rating of Moderate Buy and an average target of $105.25, while firms like Jefferies and Wells Fargo have recently raised targets to $134 and $126 respectively.
• Several insiders have sold shares recently (directors sold 3,000 and 20,000 shares), though insiders still own about 15.77% of the company.

Vanguard Group Inc. grew its stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 23.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,059,047 shares of the company's stock after acquiring an additional 391,262 shares during the period. Vanguard Group Inc. owned about 4.85% of Celcuity worth $101,717,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CELC. Bryce Point Capital LLC purchased a new position in Celcuity in the 3rd quarter valued at approximately $255,000. AlTi Global Inc. purchased a new position in shares of Celcuity in the third quarter valued at $261,000. ProShare Advisors LLC acquired a new position in shares of Celcuity during the 3rd quarter worth $249,000. Candriam S.C.A. boosted its position in shares of Celcuity by 48.3% in the 3rd quarter. Candriam S.C.A. now owns 390,924 shares of the company's stock worth $19,312,000 after buying an additional 127,348 shares in the last quarter. Finally, Murphy Pohlad Asset Management LLC acquired a new stake in Celcuity in the 3rd quarter valued at about $445,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Trading Up 4.5%

NASDAQ:CELC opened at $112.18 on Thursday. The stock has a market cap of $5.19 billion, a price-to-earnings ratio of -30.57 and a beta of 0.38. Celcuity, Inc. has a one year low of $7.57 and a one year high of $120.32. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The business's 50-day simple moving average is $106.89 and its 200 day simple moving average is $83.94.

Wall Street Analyst Weigh In

A number of brokerages have commented on CELC. Jefferies Financial Group increased their target price on Celcuity from $108.00 to $134.00 and gave the company a "buy" rating in a report on Tuesday, December 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Wednesday, January 21st. Craig Hallum lifted their price objective on Celcuity from $96.00 to $108.00 and gave the stock a "buy" rating in a research report on Thursday, November 13th. Wolfe Research started coverage on shares of Celcuity in a report on Tuesday, November 18th. They issued an "outperform" rating and a $110.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Celcuity in a report on Friday, December 12th. They set an "overweight" rating and a $126.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $105.25.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $105.69, for a total transaction of $317,070.00. Following the transaction, the director owned 6,760 shares of the company's stock, valued at $714,464.40. This trade represents a 30.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares of the company's stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 15.77% of the stock is currently owned by company insiders.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.